Cannabidiol for children with hard-to-control seizures
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests an oral cannabidiol medicine (Epidiolex) for children whose seizures are not controlled by other treatments. It aims to see if adding this drug can reduce seizure frequency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has tried at least 4 seizure medicines (or treatments like vagal nerve stimulation, brain stimulation, or the ketogenic diet) and seizures are still not controlled.
- Your child is currently taking 2 or more seizure medicines at the same dose for at least 4 weeks.
- You live in Georgia.
- Your child does not have Dravet syndrome or Lennox-Gastaut syndrome (if they are eligible for a GW Pharmaceuticals-sponsored trial).
- Your child has not been in another investigational drug trial in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This trial tests a personalized brain stimulation method (transcranial electrical stimulation) to reduce seizures in children with hard-to-control partial epilepsy. It aims to find the best stimulation spot and settings for each patient by using advanced brain scans.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.